Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT05215340
Title Study of Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in the First-line Treatment of Subjects With Advanced or Metastatic NSCLC Without Actionable Genomic Alterations (TROPION-Lung08)
Recruitment Recruiting
Gender both
Phase Phase III
Variant Requirements Yes
Sponsors Daiichi Sankyo, Inc.
Indications

lung non-small cell carcinoma

Therapies

Pembrolizumab

Datopotamab Deruxtecan + Pembrolizumab

Age Groups: adult | senior
Covered Countries USA

Additional content available in CKB BOOST